Pharma industry's investment in Finland topped $250 million last year

11 April 2016

The pharmaceutical industry’s investment in Finland totalled 220 million euros ($250 million) in 2015, the domestic trade group has said.

Pharma Industry Finland (PIF) reported that the spending was mainly on research and development, and there was also investment in production.

The group is keen to promote Finland as a good place for clinical trials and to publicize the improvement in recent years in conditions for biobank and other register-based research, which uses data collected from biobanks and other healthcare registers. It anticipates an increase in research of this type in the Scandinavian country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK